Tuesday, February 24, 2015.
In a new PLOS blog publication (link) Peter Hotez and Jennifer Herricks write about diseases that cause the most child (>5 years) deaths. Nutritional deficiencies still kill more than 200,000 young children annually, many of them from protein-energy malnutrition, but there are other causes including severe anemia that results from hookworm infection, together with other parasitic diseases. Our Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development is developing a new human hookworm vaccine in collaboration with a HOOKVAC consortium based in Europe and supported by the European Union and Dutch Government, which if successful could reduce the number of deaths from malnutrition. Continue reading
Thursday, February 19, 2015
The Health Affairs posted a blog written by Peter Hotez and Remko van Leeuwen that describes the role of HOOKVAC in vaccinating against Iron-Deficiency Anemia (IDA). As they explain: “While several factors contribute to IDA, including dietary deficiencies and iron losses through menstruation and pregnancy, human hookworm infection has been identified as one of the leading causes in impoverished countries, especially in sub-Saharan Africa, Southeast Asia, and Oceania. Hookworms are parasitic worms that attach to the inside of the intestines of children and women. Hookworms are long-lived parasites, extracting blood every day to produce sufficient blood loss that results in IDA”. Read the complete blog here: http://healthaffairs.org/blog/2015/02/19/vaccinating-against-iron-deficiency-anemia-a-new-technology-for-maternal-and-child-health/
Thursday, December 4, 2014
The Delegation of European Union to India and EuropeAid have awarded partners in the HOOKVAC consortium a grant to develop a EU-India research and innovation partnership. The following objectives are part of the grant:
- To establish an EU-India academic, cluster partnership to facilitate a long-term manufacturing partnership for the human hookworm vaccine and other NTD vaccines.
- To transfer technology from European manufacturers to Indian manufacturers for NTD vaccines
- To improve manufacturing methods to create efficiency and economy of scale
- To establish a creative environment environment for joined development of new innovative and low cost vaccines for NTDs and other poverty related diseases.
- To set-up individual mobility schemes for researchers and innovators from the HOOKVAC consortium (EU/US/ based institutes) working in research and innovation to move from the Europe cluster to India. The individual mobility schemes will be an integral component of the cluster-to-cluster partnerships.
- To support and encourage visibility, mutual understanding and awareness for low-cost vaccine development for neglected tropical diseases via meetings and workshops.
Wednesday, September 3, 2014
The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas. …read the whole press release here
Monday, September 1, 2014
As some of the world’s most urgent health threats, diseases such as polio, Ebola and influenza have of late received much publicity. Nevertheless, recent studies reveal that anaemia is also emerging as a worrying health disparity, especially among women and children living in poverty. Although perhaps not as dramatic as the infections mentioned above, anaemia has been shown to have devastating and long-term effects on childhood cognition and intellect, and to increase the risk of maternal morbidity and mortality.
Remko van Leeuwen, Martin Grobusch and Peter Hotez briefly explain why the HOOKVAC programme is now needed more than ever in the article [pdf] Tackling hookworm head-on published in ‘[pdf] Progress through Partnership: The UvA and Africa‘.
For people living in the poorest countries in Asia, Oceana, Latin America and Africa, hookworm, one of the neglected tropical diseases (NTD), is one of the leading causes of anemia. Today more than 400 million people suffer from hookworm, making it one of the most common conditions among people living in poverty. [read more at source]
New published information reveals that intestinal worm infections rank among the most common afflictions of people living in extreme poverty. The numbers are quite astonishing. More than 800 million people are currently believed to harbor Ascaris roundworms in their gastrointestinal tract, while around 450 million people are infected with either hookworms or Trichuris whipworms.
Read more on this story from the Huffingtonpost.
A new study published in Nature Genetics, led by a team of researchers at the Washington University School of Medicine in St. Louis, reveals that the hookworm’s genome has been decoded. These new developments will greatly aid scientists dr. Peter Hotez and dr. Bin Zhan at the Sabine Vaccine Institute, who focus on how different hookworm genes are responsible for invading humans, feeding on human blood and bypassing the host’s immune system. These findings have the potential to lead to new advancements and are welcome given how human hookworm, a neglected tropical disease (NTD), plagues nearly 700 million of the world’s poorest people. [Read More at the Sabine Vaccine Institute Blog]
Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease, and among the top 3 in terms of lost Disability-Adjusted Life Years.
HOOKVAC will be developing the first and only vaccine for human hookworm infection. A bivalent, low-cost vaccine candidate will be clinically tested for the first time in an African disease endemic population. This will be done in Gabon in a very typical setting within the Central African rainforest belt, where the incidence of hookworm infections is 30%. Inspired by preparatory research, HOOKVAC believes that it can develop the vaccine with at least 80% efficacy against moderate and heavy hookworm infections that lasts at five years after immunization. Cost effectiveness modelling has shown that such a vaccine will significantly improve the efficacy of the current mass drug administration programs. HOOKVAC will play a crucial role in advancing toward large scale efficacy studies in African endemic areas.
Read more about the Human Hookworm Vaccine Project.